Switch to:
Also traded in: Austria, Germany, Mexico, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.01
SHPG's Cash-to-Debt is ranked lower than
100% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. SHPG: 0.01 )
Ranked among companies with meaningful Cash-to-Debt only.
SHPG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 1.02 Max: No Debt
Current: 0.01
0.01
No Debt
Equity-to-Asset 0.59
SHPG's Equity-to-Asset is ranked lower than
63% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. SHPG: 0.59 )
Ranked among companies with meaningful Equity-to-Asset only.
SHPG' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.55 Max: 0.85
Current: 0.59
0.25
0.85
Debt-to-Equity 0.41
SHPG's Debt-to-Equity is ranked lower than
65% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. SHPG: 0.41 )
Ranked among companies with meaningful Debt-to-Equity only.
SHPG' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.3 Max: 1.12
Current: 0.41
0
1.12
Debt-to-EBITDA 2.75
SHPG's Debt-to-EBITDA is ranked lower than
68% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. SHPG: 2.75 )
Ranked among companies with meaningful Debt-to-EBITDA only.
SHPG' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.23  Med: 1.05 Max: 9.48
Current: 2.75
0.23
9.48
Interest Coverage 7.65
SHPG's Interest Coverage is ranked lower than
88% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SHPG: 7.65 )
Ranked among companies with meaningful Interest Coverage only.
SHPG' s Interest Coverage Range Over the Past 10 Years
Min: 4.16  Med: 26.47 Max: 69.47
Current: 7.65
4.16
69.47
Piotroski F-Score: 6
Altman Z-Score: 1.92
Beneish M-Score: -2.24
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 25.91
SHPG's Operating Margin % is ranked higher than
91% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. SHPG: 25.91 )
Ranked among companies with meaningful Operating Margin % only.
SHPG' s Operating Margin % Range Over the Past 10 Years
Min: 17.13  Med: 24.07 Max: 35.53
Current: 25.91
17.13
35.53
Net Margin % 30.64
SHPG's Net Margin % is ranked higher than
93% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. SHPG: 30.64 )
Ranked among companies with meaningful Net Margin % only.
SHPG' s Net Margin % Range Over the Past 10 Years
Min: 2.87  Med: 16.7 Max: 56.55
Current: 30.64
2.87
56.55
ROE % 13.33
SHPG's ROE % is ranked higher than
90% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. SHPG: 13.33 )
Ranked among companies with meaningful ROE % only.
SHPG' s ROE % Range Over the Past 10 Years
Min: 1.76  Med: 17.69 Max: 49.41
Current: 13.33
1.76
49.41
ROA % 7.22
SHPG's ROA % is ranked higher than
88% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. SHPG: 7.22 )
Ranked among companies with meaningful ROA % only.
SHPG' s ROA % Range Over the Past 10 Years
Min: 0.81  Med: 9.75 Max: 31.57
Current: 7.22
0.81
31.57
ROC (Joel Greenblatt) % 35.01
SHPG's ROC (Joel Greenblatt) % is ranked higher than
91% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. SHPG: 35.01 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SHPG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 20.13  Med: 102.56 Max: 345.74
Current: 35.01
20.13
345.74
3-Year Revenue Growth Rate 24.00
SHPG's 3-Year Revenue Growth Rate is ranked higher than
80% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. SHPG: 24.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SHPG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -0.8  Med: 14.1 Max: 32.1
Current: 24
-0.8
32.1
3-Year EBITDA Growth Rate -1.70
SHPG's 3-Year EBITDA Growth Rate is ranked lower than
58% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. SHPG: -1.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SHPG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -8  Med: 18.1 Max: 53.5
Current: -1.7
-8
53.5
3-Year EPS without NRI Growth Rate -0.70
SHPG's 3-Year EPS without NRI Growth Rate is ranked lower than
57% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. SHPG: -0.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SHPG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 14.5 Max: 65.4
Current: -0.7
0
65.4
GuruFocus has detected 7 Warning Signs with Shire PLC SHPG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SHPG's 30-Y Financials

Financials (Next Earnings Date: 2019-04-26)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2018

SHPG Guru Trades in Q1 2018

Chris Davis 1,860,234 sh (New)
Jim Simons 188,677 sh (New)
Ken Fisher 55,678 sh (+1.10%)
Richard Snow 466,549 sh (+113.54%)
John Buckingham 31,930 sh (+9.62%)
Lee Ainslie 1,713,431 sh (+3.06%)
Pioneer Investments 55,249 sh (+8.97%)
Larry Robbins 6,001,684 sh (+4.58%)
Jeff Auxier 1,705 sh (unchged)
First Eagle Investment Sold Out
John Paulson 2,952,200 sh (-3.28%)
Steven Cohen 84,000 sh (-84.92%)
Mairs and Power 3,659 sh (-5.40%)
Mario Gabelli 7,264 sh (-0.40%)
Leon Cooperman 411,872 sh (-57.99%)
» More
Q2 2018

SHPG Guru Trades in Q2 2018

Seth Klarman 98,932 sh (New)
Charles Brandes 32,141 sh (New)
Prem Watsa 7,400 sh (New)
Jeremy Grantham 453,200 sh (New)
Paul Tudor Jones 90,800 sh (New)
Louis Moore Bacon 24,800 sh (New)
Chris Davis 1,864,875 sh (+0.25%)
Pioneer Investments 72,550 sh (+31.31%)
Mario Gabelli 17,110 sh (+135.55%)
John Paulson 125,000 sh (unchged)
Steven Cohen Sold Out
Jim Simons Sold Out
Jeff Auxier Sold Out
Ken Fisher 13,295 sh (-76.12%)
Richard Snow 462,077 sh (-0.96%)
John Buckingham 31,457 sh (-1.48%)
John Paulson 2,802,200 sh (-5.08%)
Lee Ainslie 1,469,786 sh (-14.22%)
Mairs and Power 3,241 sh (-11.42%)
Larry Robbins 4,961,899 sh (-17.32%)
Leon Cooperman 122,500 sh (-70.26%)
» More
Q3 2018

SHPG Guru Trades in Q3 2018

David Abrams 2,247,133 sh (New)
Daniel Loeb 1,600,000 sh (New)
Mario Gabelli 26,542 sh (+55.13%)
Charles Brandes 76,860 sh (+139.13%)
Jeremy Grantham 566,581 sh (+25.02%)
John Paulson 2,852,200 sh (+1.78%)
Paul Tudor Jones 101,260 sh (+11.52%)
John Buckingham 31,862 sh (+1.29%)
Prem Watsa 7,400 sh (unchged)
Seth Klarman 98,932 sh (unchged)
Ken Fisher Sold Out
Leon Cooperman Sold Out
Louis Moore Bacon Sold Out
Chris Davis 1,860,595 sh (-0.23%)
Richard Snow 318,035 sh (-31.17%)
Mairs and Power 1,346 sh (-58.47%)
Pioneer Investments 41,580 sh (-42.69%)
Lee Ainslie 1,315,199 sh (-10.52%)
Larry Robbins 2,931,981 sh (-40.91%)
» More
Q4 2018

SHPG Guru Trades in Q4 2018

Jim Simons 16,900 sh (New)
Mario Gabelli 35,639 sh (+34.27%)
Daniel Loeb 1,719,413 sh (+7.46%)
Charles Brandes 84,348 sh (+9.74%)
Jeremy Grantham 762,646 sh (+34.60%)
Seth Klarman 460,473 sh (+365.44%)
Paul Tudor Jones 248,510 sh (+145.42%)
Larry Robbins 4,563,127 sh (+55.63%)
John Paulson 3,051,200 sh (+6.98%)
Prem Watsa 7,400 sh (unchged)
Mairs and Power Sold Out
David Abrams Sold Out
Chris Davis 162,332 sh (-91.28%)
Richard Snow 3,325 sh (-98.95%)
Lee Ainslie 846,406 sh (-35.64%)
Pioneer Investments 3,500 sh (-91.58%)
» More
» Details

Insider Trades

Latest Guru Trades with SHPG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BIIB, ASX:CSL, NAS:VRTX, NAS:REGN, XKRX:068270, XKRX:207940, NAS:CELG, NAS:ALXN, HKSE:01177, XMCE:GRF.P, NAS:BMRN, XBRU:UCB, NAS:NKTR, OCSE:NZYM B, NAS:INCY, OCSE:GEN, NAS:BIVV, HKSE:02269, NAS:JUNO, NAS:ALNY » details
Traded in other countries:SHPG.Austria, S7E.Germany, SHPG N.Mexico, SHP.UK, SHPGF.USA,
Headquarter Location:Ireland
Shire PLC is a biotechnology company focused mainly in the research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines for patients with rare diseases and other select conditions.

Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.

Top Ranked Articles about Shire PLC

FDA approves Shire’s Motegrity™ (prucalopride), the only serotonin-4 receptor agonist for adults with Chronic Idiopathic Constipation (CIC)
Shire Receives European Approval for TAKHZYRO™ (lanadelumab) subcutaneous injection, for the Preventive Treatment of Hereditary Angioedema
Shire plc: JAMA Publishes Complete Results of Phase 3 HELP Study™ Evaluating Lanadelumab as a Preventive Treatment for Hereditary Angioedema  
Shire Announces New HELP Study(TM) Data for Lanadelumab in HAE at 2018 ACAAI Annual Scientific Meeting
David Abrams Buys Shire, Boosts Lithia Motors Guru's largest buys of 3rd quarter
David Abrams (Trades, Portfolio), founder of Abrams Capital Management, increased his holdings of the following stocks during the third quarter. Read more...
David Abrams Buys 3 Stocks in 3rd Quarter The guru’s largest new position is Irish biotech company
David Abrams (Trades, Portfolio), the leader of Abrams Capital Management, released his third-quarter portfolio last week, listing three new holdings. Read more...
U.S. FDA Accepts for Filing Shire’s Supplemental New Drug Application for GATTEX® (teduglutide [rDNA origin]) for Children with Short Bowel Syndrome
Publication of Scheme Document
Shire Files Submission for U.S. FDA Approval to Manufacture FLEXBUMIN® at New Plasma Manufacturing Facility near Covington, Georgia
Shire plc: CHMP Recommends EU Marketing Authorisation of lanadelumab for the Prevention of HAE Attacks

Ratios

vs
industry
vs
history
PE Ratio 11.99
SHPG's PE Ratio is ranked higher than
83% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 28.79 vs. SHPG: 11.99 )
Ranked among companies with meaningful PE Ratio only.
SHPG' s PE Ratio Range Over the Past 10 Years
Min: 8.24  Med: 25.08 Max: 161.29
Current: 11.99
8.24
161.29
Forward PE Ratio 11.68
SHPG's Forward PE Ratio is ranked higher than
88% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 28.41 vs. SHPG: 11.68 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 11.99
SHPG's PE Ratio without NRI is ranked higher than
84% of the 243 Companies
in the Global Biotechnology industry.

( Industry Median: 28.64 vs. SHPG: 11.99 )
Ranked among companies with meaningful PE Ratio without NRI only.
SHPG' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.24  Med: 22.44 Max: 90.18
Current: 11.99
8.24
90.18
Price-to-Owner-Earnings 15.89
SHPG's Price-to-Owner-Earnings is ranked higher than
77% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 34.35 vs. SHPG: 15.89 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
SHPG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.7  Med: 23.87 Max: 73.04
Current: 15.89
10.7
73.04
PB Ratio 1.50
SHPG's PB Ratio is ranked higher than
85% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. SHPG: 1.50 )
Ranked among companies with meaningful PB Ratio only.
SHPG' s PB Ratio Range Over the Past 10 Years
Min: 1.01  Med: 5.12 Max: 9.45
Current: 1.5
1.01
9.45
PS Ratio 3.67
SHPG's PS Ratio is ranked higher than
79% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SHPG: 3.67 )
Ranked among companies with meaningful PS Ratio only.
SHPG' s PS Ratio Range Over the Past 10 Years
Min: 2.25  Med: 4.21 Max: 9.27
Current: 3.67
2.25
9.27
Price-to-Free-Cash-Flow 16.34
SHPG's Price-to-Free-Cash-Flow is ranked higher than
78% of the 152 Companies
in the Global Biotechnology industry.

( Industry Median: 37.07 vs. SHPG: 16.34 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SHPG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.96  Med: 20.52 Max: 43.8
Current: 16.34
8.96
43.8
Price-to-Operating-Cash-Flow 13.33
SHPG's Price-to-Operating-Cash-Flow is ranked higher than
82% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 29.99 vs. SHPG: 13.33 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SHPG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.55  Med: 15.52 Max: 26.33
Current: 13.33
7.55
26.33
EV-to-EBIT 22.23
SHPG's EV-to-EBIT is ranked lower than
52% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. SHPG: 22.23 )
Ranked among companies with meaningful EV-to-EBIT only.
SHPG' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.8  Med: 20 Max: 174.4
Current: 22.23
11.8
174.4
EV-to-EBITDA 12.81
SHPG's EV-to-EBITDA is ranked higher than
65% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. SHPG: 12.81 )
Ranked among companies with meaningful EV-to-EBITDA only.
SHPG' s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.6  Med: 14 Max: 52.8
Current: 12.81
10.6
52.8
EV-to-Revenue 4.67
SHPG's EV-to-Revenue is ranked higher than
74% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. SHPG: 4.67 )
Ranked among companies with meaningful EV-to-Revenue only.
SHPG' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.6  Med: 4.6 Max: 10
Current: 4.67
2.6
10
PEG Ratio 0.78
SHPG's PEG Ratio is ranked higher than
82% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 2.02 vs. SHPG: 0.78 )
Ranked among companies with meaningful PEG Ratio only.
SHPG' s PEG Ratio Range Over the Past 10 Years
Min: 0.47  Med: 0.94 Max: 75.51
Current: 0.78
0.47
75.51
Shiller PE Ratio 30.54
SHPG's Shiller PE Ratio is ranked higher than
69% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 42.91 vs. SHPG: 30.54 )
Ranked among companies with meaningful Shiller PE Ratio only.
SHPG' s Shiller PE Ratio Range Over the Past 10 Years
Min: 21.14  Med: 90.24 Max: 469
Current: 30.54
21.14
469
Current Ratio 0.92
SHPG's Current Ratio is ranked lower than
82% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. SHPG: 0.92 )
Ranked among companies with meaningful Current Ratio only.
SHPG' s Current Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.52 Max: 7.43
Current: 0.92
0.52
7.43
Quick Ratio 0.51
SHPG's Quick Ratio is ranked lower than
86% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. SHPG: 0.51 )
Ranked among companies with meaningful Quick Ratio only.
SHPG' s Quick Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.35 Max: 7.07
Current: 0.51
0.4
7.07
Days Inventory 264.59
SHPG's Days Inventory is ranked lower than
82% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. SHPG: 264.59 )
Ranked among companies with meaningful Days Inventory only.
SHPG' s Days Inventory Range Over the Past 10 Years
Min: 126.5  Med: 190.89 Max: 276.29
Current: 264.59
126.5
276.29
Days Sales Outstanding 76.56
SHPG's Days Sales Outstanding is ranked lower than
57% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. SHPG: 76.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
SHPG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.71  Med: 71.72 Max: 83.8
Current: 76.56
47.71
83.8
Days Payable 323.67
SHPG's Days Payable is ranked lower than
99.99% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. SHPG: 323.67 )
Ranked among companies with meaningful Days Payable only.
SHPG' s Days Payable Range Over the Past 10 Years
Min: 71.02  Med: 110.24 Max: 323.67
Current: 323.67
71.02
323.67

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.59
SHPG's Dividend Yield % is ranked lower than
73% of the 226 Companies
in the Global Biotechnology industry.

( Industry Median: 1.08 vs. SHPG: 0.59 )
Ranked among companies with meaningful Dividend Yield % only.
SHPG' s Dividend Yield % Range Over the Past 10 Years
Min: 0.23  Med: 0.45 Max: 0.85
Current: 0.59
0.23
0.85
Dividend Payout Ratio 0.07
SHPG's Dividend Payout Ratio is ranked higher than
98% of the 131 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. SHPG: 0.07 )
Ranked among companies with meaningful Dividend Payout Ratio only.
SHPG' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.04  Med: 0.1 Max: 0.35
Current: 0.07
0.04
0.35
3-Year Dividend Growth Rate 19.90
SHPG's 3-Year Dividend Growth Rate is ranked higher than
74% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 6.30 vs. SHPG: 19.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
SHPG' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 14.3 Max: 57.8
Current: 19.9
0
57.8
Forward Dividend Yield % 0.59
SHPG's Forward Dividend Yield % is ranked lower than
74% of the 221 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. SHPG: 0.59 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.72
SHPG's 5-Year Yield-on-Cost % is ranked higher than
60% of the 219 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. SHPG: 1.72 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
SHPG' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.67  Med: 1.31 Max: 2.48
Current: 1.72
0.67
2.48
3-Year Average Share Buyback Ratio -15.60
SHPG's 3-Year Average Share Buyback Ratio is ranked lower than
55% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. SHPG: -15.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SHPG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -28.8  Med: -1.7 Max: 7.1
Current: -15.6
-28.8
7.1

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.87
SHPG's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
92% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 3.12 vs. SHPG: 0.87 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
SHPG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.7  Med: 1.51 Max: 2.95
Current: 0.87
0.7
2.95
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.12
SHPG's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
99.99% of the 38 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. SHPG: 1.12 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
SHPG' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.92  Med: 2.03 Max: 8.09
Current: 1.12
0.92
8.09
Price-to-Median-PS-Value 0.87
SHPG's Price-to-Median-PS-Value is ranked higher than
58% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. SHPG: 0.87 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SHPG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.57  Med: 1.02 Max: 2.97
Current: 0.87
0.57
2.97
Price-to-Peter-Lynch-Fair-Value 0.97
SHPG's Price-to-Peter-Lynch-Fair-Value is ranked higher than
78% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 1.72 vs. SHPG: 0.97 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
SHPG' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.54  Med: 1.01 Max: 5.86
Current: 0.97
0.54
5.86
Earnings Yield (Greenblatt) % 4.50
SHPG's Earnings Yield (Greenblatt) % is ranked higher than
87% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. SHPG: 4.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SHPG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.6  Med: 5 Max: 8.4
Current: 4.5
0.6
8.4
Forward Rate of Return (Yacktman) % 18.23
SHPG's Forward Rate of Return (Yacktman) % is ranked higher than
67% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 11.41 vs. SHPG: 18.23 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
SHPG' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.1  Med: 21.7 Max: 23.9
Current: 18.23
1.1
23.9

More Statistics

Revenue (TTM) (Mil) $15,701.80
EPS (TTM) $ 15.75
Volatility24.46%
52-Week Range $123.73 - 182.47
Shares Outstanding (Mil)306.04 (ADR)

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 15,687 16,026 16,980
EBIT (Mil $) 5,202 5,698 6,995
EBITDA (Mil $) 6,968 7,410 8,458
EPS ($) 8.64 10.41 12.30
EPS without NRI ($) 8.64 10.41 12.30
EPS Growth Rate
(Future 3Y To 5Y Estimate)
3.19%
Dividends per Share ($) 1.12 1.25 1.49

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}